Ma and other studies have found that CCAT1 can promote high levels of myosin light chain kinase (MLCK) expression by acting as a molecular sponge of miRNA and competitively binding to miR-185-3p, leading to an increase in intestinal barrier permeability and the weakening of intestinal mucosal barrier function in patients with IBD, resulting in malignant diseases [43]. The gene discussed is MYLK; the disease is irritable bowel syndrome.